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ABSTRACT 
 
Carbapenems are β-lactam antibiotics reserved for the treatment of severe 
microbial infections, especially those targeting the Enterobacteriaceae. Introduced in 
the 1980s, carbapenems have been used successfully in hospitals, and in the 1990s 
resistance was discovered. Carbapenem resistance is conferred through the production 
of carbapenemases. In the U.S., the most common carbapenemase is Klebsiella 
pneumoniae carbapenemase (KPC). In 2012, the National Healthcare Safety Network 
reported a carbapenem resistance rate of 13.0% among Klebsiella pneumoniae 
infections, and indicated that the mortality rate associated with carbapenem resistant 
Enterobacteriaceae (CRE) infections ranged from 48.0-71.9%.  According to the Food 
and Drug Administration (FDA), carbapenem resistance is observed when a pure culture 
has a minimum inhibitory concentration (MIC) ≥ 4 g/ml as determined through 
antibiotic susceptibility testing (AST).In 2012, a lower MIC for carbapenem antibiotics 
was established for KPCs by the Clinical and Laboratory Standards Institute (CLSI) (i.e., 
MICs 1 - 4 g/ml are designated resistant), but these criteria have not been endorsed by 
the FDA. Data are needed to determine the percentage of clinical isolates with 
carbapenem MIC between 1 and 4 g/ml that are truly resistant. Determining the 
presence of the KPC gene is important because the use of carbapenems in patients with 
MIC between 1- 4 g/ml may have poor clinical outcomes. Conversely, if lacking the KPC 
gene, carbapenems may still be indicated. The objectives of this study were to 
determine the presence of the KPC gene, the carbapenem AST profiles of clinical 
isolates, and the resistance rates based on the previous and current CLSI criteria. This 
study involved 56 suspected CRE clinical isolates from Las Vegas, Nevada, which were 
analyzed by culture, AST, and polymerase chain reaction to detect the KPC gene. The 
prevalence of the blaKPC gene in our CRE isolates was 83.3%, and the prevalence was 
94.7% among our Klebsiella pneumoniae isolates. Our data showed no statistically 
significant difference between the previous and the current CLSI criteria in defining 
carbapenem resistance among the Enterobacteriaceae. The results from this study 
helped determine the prevalence of the KPC gene and antimicrobial susceptibility 
profiles among CRE isolates in Las Vegas. These may be useful in improving antibiotic 
stewardship in Nevada. 
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INTRODUCTION 
The Enterobacteriaceae is a family of bacteria with many different genera and 
species. Members of this family are gram negative, non-spore forming, and facultative 
anaerobes, which include many opportunistic and pathogenic species.  Most of these 
organisms are present in the intestinal tracts of humans and animals, while some are 
freely living in soil, water and sewage. Opportunistic Enterobacteriaceae cause disease 
when the immunity is low, and are usually in the intestinal and skin flora of humans and 
animals, but can produce serious infection outside their natural habitat.  Clinical isolates 
of Enterobacteriaceae that are commonly seen in acute and long term care centers are  
Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (Mahon, Manuselis, & 
Lehman, 2010). Other common genera include Shigella spp., Salmonella spp., 
Citrobacter spp., Yersinia, Serratia spp., etc. (Mahon et al., 2010). These organisms are  
notorious for causing mild to severe infections, such as cystitis, pneumonia, meningitis, 
bacteremia, septicemia, and wound infections, when immunity is compromised 
(Schwaber & Carmeli, 2008).  
 Klebsiella pneumoniae is a common opportunistic and nosocomial organism. It is 
an encapsulated non-motile gram negative bacterium found as normal flora of the 
human skin, mouth and the intestines. However, it is capable of causing serious 
infection. The distinct polysaccharide capsule of Klebsiella pneumoniae offers protection 
against phagocytosis and antimicrobial absorption, and contributes to its virulence 
(Mahon, Manuselis, & Lehman, 2000).  The frequent colonization by Klebsiella 
pneumoniae of the respiratory tracts of hospitalized patients makes it a common cause 
of lower respiratory infection, especially among immunocompromised patients, 
newborns and patients on respirators. K. pneumoniae remains the fourth and fifth most 
common cause of acute pneumonia and bacteremia in hospital intensive care units, 
respectively (Centers for Disease Control and Prevention, 2003). It can also cause 
serious infections outside the hospital, and has been estimated to be responsible for 6% 
- 8% of community acquired pneumonia (Jong, Hsiue, Chen, Chang, & Chen, 1995).  
Other community acquired infections caused by K. pneumoniae include wound 
infections, abscesses, and urinary tract infections.  
Cephalosporins and the β-lactams are common antimicrobial agents used 
successfully in the treatment of infections caused by Klebsiella pneumoniae and other 
Enterobacteriaceae. In the past, 3rd and 4th generation cephalosporins were first choice in 
the treatment of Enterobacteriaceae infections. However, resistance of 
Enterobacteriaceae to these antibiotics has been well documented in recent times 
(Paterson et al., 2003; Saurina, Quale, Manikal, Oydna, & Landman, 2000).  
Carbapenems are β-lactamase inhibitor antibiotics. The parent or model compound of 
carbapenems is thienamycin, a compound from Streptomyces cattleya which was first 
reported in 1976 (Ratcliffe & Albers-Schonberg, 1982). Thienamycin has a hydroxyethyl 
side chain, a departure from the conventional structures of penicillin and 
cephalosporins (Papp-Wallace, Endimiani, Taracila, & Bonomo, 2011). This 
stereochemistry and structure are key to their extensive activity and potency.  
Unfortunately, thienamycin is unstable in aqueous solution, highly reactive and very 
sensitive to mild base hydrolysis. This instability stimulated the search for more stable 
thienamycin analogs.   
Carbapenems, such as Ertapenem, Imipenem, Meropenem, and Doripenem are 
analogs of thienamycin, and  unlike thienamycin, they are more stable and less sensitive 
to base hydrolysis (Branch et al., 1998). They possess the widest spectrum of 
antibacterial activities and potency of all the  β-lactam antibiotics and are effective 
against gram negative and gram positive organisms (Bassetti, Nicolini, Esposito, Righi, & 
Viscoli, 2009; Papp-Wallace et al., 2011). Carbapenems are active against the 
chromosomal cephalosporinases and extended-spectrum β-lactamases, both of which 
are found in resistant gram-negative organisms (G. A. Jacoby & Munoz-Price, 2005; 
Queenan & Bush, 2007). Another mechanism of action of carbapenems involves the 
destruction of bacterial membranes through porin proteins leading to permeability.  
Carbapenems form part of a new generation of antibiotics that are reserved for the 
treatment of severe and resistant microbial infections, especially those caused by 
Enterobacteriaceae. Since their discovery in 1985, carbapenems have been remarkably 
effective in the treatment of severe infections, and in some situations, they are 
regarded as the last resort for treatment of infections caused by extended spectrum β-
lactamase (ESBL) organisms (Remington, 1985).  
Carbapenem resistance first appeared sporadically in the mid-1990s, in places 
such as Spain (Corbella et al., 2000). Though the resistance was uncommon, in recent 
years, carbapenem resistant Enterobacteriaceae (CRE) outbreaks have been 
progressively increasing (Queenan & Bush, 2007; Schwaber et al., 2008). Beyond 
Enterobacteriaceae, many non-fermenting gram negatives (e.g., Pseudomonas and 
Acinetobacter species) and some gram positives (e.g., Staphylococcus, Streptococcus, 
Enterococcus, and Nocardia species) are also becoming resistant to carbapenems. This 
pattern represents a major public health threat in our society. In the U.S., CREs were 
first discovered in North Carolina in 2001 (Yigit et al., 2001). Since then, outbreaks have 
been reported throughout the country, especially in the northeast region (Landman et 
al., 2007; Queenan & Bush, 2007).  
 Unlike Methicillin Resistant Staphylococcus aureus (MRSA) resistance, which is 
mediated by a single mechanism in a single bacterial species, the mechanisms of 
carbapenem resistance are complex because they involve a broad range of organisms 
and are mediated by different mechanisms, such as the production of β-lactamases, 
efflux pump and porin mutations. Carbapenemases are β-lactamases with versatile 
hydrolytic capacities and are capable of hydrolyzing the beta-lactam ring of 
carbapenems. They are also capable of hydrolyzing penicillins, monobactams, and 
cephalosporins. Carbapenemases are the most prominent β-lactamases to neutralize 
carbapenems (Nordmann & Poirel, 2002; Queenan & Bush, 2007). 
Carbapenemases are enzymes that catalyze the breakdown of carbapenems.  
They confer resistance to carbapenems and belong to the molecular classes A, B, and D 
of the β-lactamases. Class A and D enzymes have a serine-based hydrolytic mechanism, 
while class B uses zinc in their active site.  Klebsiella pneumoniae carbapenemase (KPC) 
is a class B β-lactamase and is the most common form of carbapenemase implicated in 
CRE outbreaks in the U.S.  Sometimes sporadic outbreaks involve the New Delhi 
Metallo-β-lactamase (NDM-1), a variant of the Metallo- β -lactamases (MBL). Other 
forms of carbapenem resistance, such as the production of AmpC-type enzyme with a 
combination of cephalosporinase and porin loss are increasingly becoming common 
(Bradford et al., 2004; Crowley, Benedi, & Domenech-Sanchez, 2002; Queenan & Bush, 
2007). Other countries with KPC outbreaks include Greece, Israel, Colombia, and Puerto 
Rico (Leavitt, Navon-Venezia, Chmelnitsky, Schwaber, & Carmeli, 2007).  
The genes coding for the KPC are located on plasmids or the mobile units of 
Klebsiella DNA. This property makes the KPC gene easily transmissible. Not surprisingly, 
KPC genes have been successfully isolated from other Enterobacteriaceae, such as 
Escherichia coli, Serratia marcescens, Pseudomonas, and Acinetobacter baumannii 
(Deshpande, Jones, Fritsche, & Sader, 2006; Patel & Bonomo, 2011; Villegas et al., 
2007).  
Klebsiella pneumoniae Sequence Type 258 (ST258), which is a single locus variant 
of Sequence Type 11 (ST11), is the most common clone or strain type of Klebsiella 
implicated in the KPC-producing K. pneumoniae. This strain accounts for over 70% of the 
CDC’s Klebsiella pneumoniae Pulse Field Gel Electrophoresis (PFGE) database (Kitchel et 
al., 2009). ST258 isolates demonstrate great diversity in molecular characteristics and 
epidemiology, and have been identified in KPC-producing isolates from Israel, Finland, 
Poland, Italy, Germany, Greece, Norway and Sweden, supporting possible international 
dissemination (Cuzon, Naas, Demachy, & Nordmann, 2008; Qi et al., 2011; Samuelsen et 
al., 2009).  K. pneumoniae Sequence Type 14 (ST14) has also been identified, but it is 
associated with KPC-producing isolates from the Midwest and Western U.S., (Kitchel et 
al., 2009).  ST11, which is closely related to ST258, is the dominant KPC-producing K. 
pneumoniae in China, and it accounts for greater than 80% of China’s KPC-producing K. 
pneumoniae isolates  (Qi et al., 2011) 
Epidemiology of CRE 
CREs appeared to be uncommon before 1992; however, over the last decades 
CRE infections have become commonly reported (Braykov, Eber, Klein, Morgan, & 
Laxminarayan, 2013). CRE outbreaks have been reported in at least 43 states in the U.S. 
and many other countries such as Brazil, Israel, Greece, and India (Andrade et al., 2011; 
Centers for Disease Control and Prevention, 2012a; Gupta, Limbago, Patel, & Kallen, 
2011; Pournaras et al., 2009). The Centers for Disease Control and Prevention (CDC) 
monitor the true incidence of infections caused by CREs; unfortunately, CRE infections 
are not notifiable in every state. The CDC uses information from two surveillance 
systems; namely, the Emerging Infection Program (EIP) and the National Healthcare 
Safety Network (NHSN), to monitor CRE infection incidences. The NHSN reviews data 
from all facilities performing surveillance for Central-Line-Associated Bloodstream 
Infections (CLABSI) together with data from Catheter Associated Urinary Tract 
Infections (CAUTIs). These infections, mainly caused by Enterobacteriaceae, such as E. 
coli, K. pneumoniae, K. oxytoca, Enterobacter cloacae, and Enterobacter aerogenes 
have showed non-susceptibility to Ertapenem, Imipenem, Doripenem or Meropenem. 
The EIP uses population-based CRE surveillance data from three selected sites in the 
U.S. 
 Data from the National Nosocomial Infection Surveillance (NNIS), (before it was 
replaced by NHSN) reported that between 1986 and 1990, the rate of non-
susceptibility to carbapenem in 1,825 isolates of Enterobacter investigated was 2.3% 
(Gaynes & Culver, 1992). It also reported that the percentage of Enterobacteriaceae 
that were carbapenem resistant rose from 1.2% in 2001 to 4.2%  in 2011 (Jacob et al., 
2013). These rates vary among Enterobacteriaceae and have increased the most in 
Klebsiella species, from 1.6 % to 10.8 %. Data from The Surveillance Network (TSN),  
which represents an electronic repository of susceptibility test results from over 300 
laboratories across the United States, demonstrated an increase from 0% to 1.2% 
among all CREs, and 0% to 5.3% among Klebsiella species (Jacob et al., 2013).  Data 
from the Meropenem Yearly Susceptibility Test Information Collection Program 
(MYSTICP), between 2006 and 2007,  reported that resistance among Klebsiella 
pneumoniae exceeded 8% before falling momentarily to 5.6% in 2008 (Braykov et al., 
2013; Rhomberg & Jones, 2009). The NHSN, in 2004, reported a CRE rate of 10.8% 
among Klebsiella pneumoniae; that stabilized at 13% in 2012 (Hidron et al., 2008; 
Sievert et al., 2013). The Washoe County Health District in Nevada in 2011,  reported 
an incidence rate of 5%, after 15 months of CRE surveillance on 111 clinical isolates 
tested with the Modified Hodge Test at the Nevada State Public Health Laboratory 
(Chen, 2011). Interestingly, the majority of the CRE isolates in Washoe County were 
Enterobacter cloacae, an organism that has shown resistance to carbapenems. 
During the first half of 2012, a surveillance of CAUTIs and CLABSI in acute-care 
hospitals in the U.S. reported that 181 of 3,918 (4.6%) centers surveyed reported 
detecting one or more infections with CREs.  Long-term acute care hospitals (LTACHs) 
have reported a rate of 17.8% in at least one outbreak of CRE infections, while, in short-
term acute care hospitals, rates were 3.9%. The highest percentage of hospitals with 
CREs were in the northeast U.S., where rates were up to 30%.  In the 2012 NHSN report, 
the state of Nevada was included  as one of 43 states with CRE infections in the U.S. 
(Jacob et al., 2013). 
Detection of CRE 
The most often used method for CRE detection is the measurement of Minimal 
Inhibitory Concentration (MIC) through automated susceptibility testing machines. MIC 
is a quantitative measurement of antibiotic activities, and it is defined as the minimum 
concentration of an antibiotic that can inhibit visible microbial growth under normal 
conditions (Mayer, 2010; Sievert et al., 2013). Carbapenem resistance is defined for all 
organisms as an MIC result of Intermediate (I) or Resistant (R) to carbapenems on any 
antibiotic susceptibility test (Sievert et al., 2013). According to the FDA, an organism is 
classified as resistant to carbapenem if the pure culture shows a microbial breakpoint 
with an MIC ≥ 4 g/ml during susceptibility testing (Bulik et al., 2010). Microbial 
breakpoint refers to the MIC at which an organism is described as susceptible or 
resistant to a given antibiotic. It is important that the MIC of antibiotics be lower than 
their breakpoint.  
Carbapenem resistance can also be determined using the disk diffusion method.  
A type of disk diffusion method used is the Modified Hodge Test (MHT), a form of 
susceptibility testing that phenotypically determines the presence of the 
carbapenemase enzyme (Clinical and Laboratory Standards Institute, 2012). The MHT 
has been regarded as the confirmatory test for CRE; however, limitations to this method 
include an inability to differentiate the class of carbapenemase involved, unusable for 
non-fermenting organisms, long duration of testing (up to 36 hours for the results to be 
available), a low positive predictive valve, and variable sensitivity that ranges from 76% 
to 100% (Amjad et al., 2011; Haji Hashemi et al.; Mathers, Carroll, Sifri, & Hazen, 2013; 
Tsakris et al., 2010).    
 The use of boronic acid is another phenotypic test for detecting CREs and has 
demonstrated an excellent ability in detecting KPCs, especially among Klebsiella 
pneumoniae isolates (Doi et al., 2008). Boronic acid alone or in combination with disks 
containing Imipenem, Meropenem or cefepime, showed 100% sensitivity and specificity 
in identifying  KPC producers (Tsakris et al., 2009).  Unfortunately, this method is not 
commercially available, and like the MHT, it requires an additional day before results are 
available.  
Real-time Polymerase Chain Reaction (PCR) is a quick, accurate and effective 
method of CRE detection; it can detect CRE resistance genes, such as the blaKPC, the 
NDM-1, MBL, and the AmpC genes (Endimiani et al., 2010). PCR and other molecular 
tests have the highest specificity in identification and confirmation of the underlying 
carbapenemases (Nordmann et al., 2012).  The sensitivity of real-time PCR in detecting 
the blaKPC gene ranges from 92.9% to 96.4% while the specificity is as high as 99.6% 
(Francis, Wu, Della-Latta, Shi, & Whittier, 2012).  However, the high cost and the 
technical expertise required, in addition to the fact that only the target gene (e.g., 
carbapenemase gene) amplifies, are significant limitations to the use of PCR and other 
molecular tests in CRE detection (Yang & Rothman, 2004). 
    A significant problem in CRE laboratory detection is the fact that some bacterial 
isolates carry the KPC gene, while having susceptible, but  elevated MICs (Clinical and 
Laboratory Standards Institute, 2009). This means that some isolates producing 
carbapenemase may test susceptible to carbapenems. In these situations, CREs will not 
be identified, thus posing an infection control problem. This has caused some 
automated AST methods to fail in detecting low levels of carbapenemase resistance.  
To tackle this problem, the Clinical and Laboratory Standards Institute (CLSI), in 
2009, published a recommendation that carbapenem susceptible Enterobacteriaceae 
with susceptible, but elevated MIC or with a reduced disk diffusion zone, be tested for 
the presence of the carbapenemase enzyme using the Modified Hodge Test. 
Furthermore, in 2010, the CLSI officially changed the carbapenem resistance criteria to 
ensure that KPC-producing organisms were not missed.  This, also, removed the need 
for secondary testing with MHT among isolates with susceptible but elevated MICs. 
Therefore, a lower level of MIC for antibiotic resistance was established for CREs; these 
criteria were further revised in 2012 (Clinical and Laboratory Standards Institute, 2012). 
The previous and the current CLSI criteria are shown in Table 1. 
  
Table 1: Performance Standards for Antimicrobial Susceptibility Testing. 
Agent 
Previous Breakpoints (M100-S19)a  
MIC (g/ml) 
Current Breakpoints (M100-S22)b  
MIC (g/ml) 
S I R S I R 
Doripenem - - - ≤1 2 ≤4 
Ertapenem ≤2 4 ≥8 ≤0.5 1 ≥2 
Imipenem ≤4 8 ≥16 ≤1 2 ≥4 
Meropenem ≤4 8 ≥16 ≤1 2 ≥4 
S = Susceptible; I= Intermediate; R = Resistant; MIC = minimum inhibitory concentration 
a 2009 CLSI criteria 
b 2012 CLSI criteria 
Source:  Twenty Second Informational Supplement (January 2012). CLSI document M100-S22. 
Wayne, Pennsylvania, 2012. 
 
Diagnostic kit manufacturers and clinical laboratories must have their kits FDA-
cleared before they can be used with patient isolates; these recent changes have led to 
confusion (Gupta et al., 2011). As of late 2010, about 80% of clinical laboratories still use 
FDA-cleared AST systems with FDA breakpoints (Paxton, 2010).  An Indiana Sentinel 
Laboratories CRE Testing Capacity Survey that studied the adoption rate of the new CLSI 
criteria noted that only about 37% of laboratories in Indiana used the CLSI M100-S21 
criteria (Jean, 2011). In Rhode Island, a statewide assessment of the impact of the new 
CLSI criteria conducted in 2012 found that 100% of the 11 clinical laboratories 
representing all the state’s acute care centers did not use the new CLSI criteria 
(Alexander, 2013). At the same time, only 27% of these laboratories in Rhode Island 
were interested in conducting the necessary verification studies to implement the 
current CLSI criteria. The majority of laboratories and hospitals preferred to wait until 
the manufacturers update their AST systems when the FDA accepts the new CLSI criteria 
(Alexander, 2013). These are undoubtedly key obstacles to the widespread adoption of 
the new CLSI breakpoints.  However, the FDA has started this ratification process by 
releasing guidance that informs pharmaceutical companies and manufacturers of the 
need to review their drug package information and revise them to meet current drug 
testing criteria (Food and Drug Adminstration, 2009). Unfortunately, this problem may 
persist for some time, because the regulatory system by which the FDA updates or 
modifies drug labels and information can move slowly (Paxton, 2010). Until the FDA 
approves the new CLSI breakpoints for AST system manufacturers, inadequate 
surveillance and control of CRE will continue to pose a problem. In the meantime, it is 
recommended that institutions and clinical laboratories adopt the new CLSI criteria if 
they can conduct an in-house confirmatory susceptibility testing (Paxton, 2010).  
Relevance to Public Health 
CREs and KPCs are particularly important in public health because of the high 
mortality associated with their infections and the tendency to spread beyond health 
centers (Bratu et al., 2005; Patel, Huprikar, Factor, Jenkins, & Calfee, 2008).  In terms of 
cost of treatment, an estimated  $21 billion -  $34 billion are spent annually in the 
treatment of CREs in the U.S. (Spellberg et al., 2011).  
 Some major risk factors for acquiring CRE are exposure in health care facilities, 
erratic use of antibiotics, a history of recent organ transplant (including stem-cell 
transplantation), the use of mechanical ventilation and longer hospital stay. These risks 
are also independently associated with higher mortality due to CREs (Patel et al., 2008). 
Other risk factors associated with higher mortality among patients with CRE infections 
include deteriorating health status, intensive care unit admission, and the use of 
invasive medical instrumentation, etc., (Falagas et al., 2007; Schwaber et al., 2008). A 
mortality rate of 48% has been reported among patients with CRE infections, and a 
crude mortality rate as high as 71.9% has been reported by some researchers (Patel et 
al., 2008).  
There is a high potential for extensive spread of the carbapenem resistance gene 
from one Enterobacteriaceae into another within a health institution or to the 
community through mobile transmissible genetic components on the KPC gene 
(Watanabe, Iyobe, Inoue, & Mitsuhashi, 1991; Yigit et al., 2001). CREs are mainly seen in 
long term acute care (LTAC) centers. This suggests that LTACs could be a potential 
reservoir for CREs (Perez et al., 2010).  Although the focus of CRE prevention has been 
on acute care settings (long and short term), there have been documented cases of 
CREs in non-acute care settings, for example, in long term care facilities, such as nursing 
homes and assisted living facilities (Urban et al., 2008). Therefore, limiting prevention 
and control efforts to acute care centers might be counterproductive.  
 CREs are not a problem limited to individual facilities. They can affect entire 
communities and nations, which highlights the role of public health in this issue. Public 
health organizations have the capacity to reach across all care institutions and to 
improve community situational awareness with regards to CREs and coordination of 
prevention efforts.  For example, in Israel, a centrally coordinated effort  by the Israel 
Carbapenem-Resistant Enterobacteriaceae Working group has been helpful in 
decreasing the incidence of CREs  (Schwaber et al., 2011). 
The implementation of the new CLSI’s MIC guidelines and breakpoints can have a 
significant impact on carbapenem AST reports from clinical diagnostic laboratories, with 
associated alterations in antibiotic prescription by clinicians (MacKenzie et al., 2007). 
Therefore, accurate laboratory information, better knowledge of the patient’s history, 
and current information about CREs are all necessary to avoid uncertainties in 
carbapenem AST reports (Endimiani et al., 2009).  
In Nevada, data are needed to determine the percentage of isolates with 
carbapenem MIC from the current CLSI breakpoints that are truly resistant to 
carbapenems, by the presence of the resistant KPC gene (Endimiani et al., 2009). The 
objectives of this study were to determine the presence of the KPC gene and the 
carbapenem antimicrobial resistance profiles of clinical isolates from health care 
facilities in Nevada for the purpose of determining if there is a difference in the rate of 
resistance between the previous and the current CLSI criteria. 
RESEARCH QUESTIONS 
 
1. What is the percentage of CRE isolates that are positive for the KPC gene using the 
current CLSI criteria for resistance to carbapenems? 
2. What is the mechanism of resistance seen in CRE isolates? 
3. Is there a benefit in adopting the new CLSI carbapenem guidelines?  
HYPOTHESES 
 
Ho1: There is no difference between carbapenem resistance in clinical isolates with the 
previous breakpoints and the current breakpoints. 
HA1: There is a difference between carbapenem resistance in clinical isolates with the 
previous breakpoints and the current breakpoints. 
 
Ho2: There is no difference in carbapenem susceptibility profiles among KPC gene 
positive isolates between the current and the previous CLSI breakpoints. 
HA2: There is a difference in carbapenem susceptibility profiles among KPC gene positive 
isolates between the current and the previous CLSI breakpoints. 
 
MATERIALS AND METHODS 
Test Organisms 
Pure cultures from clinical isolates suspected of being carbapenem-resistant 
Enterobacteriaceae (de-identified of patient data) were obtained from Quest 
Diagnostics in Las Vegas, Nevada, and were transported to the Emerging Diseases 
Laboratory (EDL) at the University of Nevada, Las Vegas, for analysis. Enterobacteriaceae 
strains were obtained from the American Type Culture Collection (ATCC, Manassas, VA), 
and were used as quality control (QC) organisms. Two of these ATCC organisms are 
carbapenem resistant and possess the KPC gene, while four of these strains are 
susceptible to carbapenems and do not possess the KPC gene (Table 2). 
Table 2: Test Organisms Obtained from the American Type Culture Collection (ATCC). 
Test Organism ATCC# blaKPC gene 
Klebsiella pneumoniae 13883 Negative 
Klebsiella pneumoniae 4352 Negative 
Klebsiella pneumoniae 700603 Negative 
Klebsiella pneumoniae BAA 1706 Negative 
Klebsiella pneumoniae BAA 1705 Positive 
Enterobacter hormaechi BAA 2082 Positive 
 
Lyophilized ATCC strains were re-suspended in nuclease-free water (HyClone 
Laboratories, Logan, Utah), vortexed, and cultured on Tryptic Soy Agar (TSA) (Becton 
Dickinson, Sparks, MD).  All clinical isolates were stored at 4°C upon arrival and re-
streaked onto fresh TSA plates (Becton Dickinson) within 48 hours of receipt. QC 
organisms and clinical isolates were incubated at 35°C in ambient air for 24-48 hours.  
Isolated colonies were picked and used to prepare freezer and refrigerator stocks. 
Freezer stocks were prepared by transferring two to three isolated colonies to a 
2 ml cryogenic tube containing 500 l of Tryptic Soy Broth ( Becton Dickinson) and 500 
l of sterile glycerol (MP Biomedicals, Solon, Ohio). The tube was vortexed vigorously 
for 30 seconds or until the colonies were completely re-suspended, followed by 
incubation in a rotary shaker at 35°C for 30 minutes and 175 rpm.  Freezer stocks were 
stored at -70°C. Refrigerator stocks were prepared by re-streaking an isolated colony 
from the 24-48 hours TSA plate onto a TSA slant (Becton Dickinson), incubated 
overnight at 35°C ambient air, and stored at 4°C.   
  Two to three isolated colonies from the 24-48 hours TSA plate were transferred 
to a micro-centrifuge tube containing 400 l of nuclease free water (HyClone 
Laboratories). The suspension was vortexed for 15 – 30 seconds for proper 
homogenization, and stored at -70°C for DNA extraction.  
DNA Extraction 
Bacterial DNA was extracted using the MoBio PowerSoil DNA extraction kit 
(MoBio, Carlsbad, CA) according to the manufacturer’s instructions with one exception; 
200 μl of sample (instead of 0.25g) was used for extraction. The DNA extract was eluted 
in 100 μl of the C6  buffer solution provided, and stored at –70°C until ready for use.  
Template DNA Concentration 
 After DNA extraction, the amount of DNA in each sample extract was measured 
with a Spectronic TM Genesys 10 BIO UV- Visible  spectrophotometer (Thermo Fisher 
Scientific, Madison, WI) using the nanoCell accessory – 0.2mm path length. Briefly, 1.0 
µl of the sample extract was used, after zeroing the spectrophotometer with the C6 
solution from the PowerSoil DNA extraction kit. The absorbance was set at 260/280 nm, 
with 320 nm reference wavelength and 2500 dilution factor. Samples were measured in 
duplicate and DNA concentrations were expressed in ng/µl. All samples with DNA 
concentration of 21 ng/µl and above were diluted using Tris-EDTA (TE) buffer (Teknova, 
Hollister, CA) prior to the PCR assay. This enabled the  DNA in the PCR to maintain a 
concentration between 10 – 100 ng (Life Technologies). 
Real-Time Polymerase Chain Reaction (PCR) 
 The 7900 HT Fast PCR System (Applied Biosystems, Foster City, CA) was used for 
detection and amplification of the blaKPC gene. Primers and a fluorescent probe specific 
for the blaKPC gene were identified from the literature that produced a 246-bp 
amplicon (Hindiyeh et al., 2008; Tenover et al., 2006). The master mix was prepared 
using TaqMan 1X Universal Master Mix (Branchburg, New Jersey),  sterile Nuclease Free 
Water (Promega, Madison, WI), 0.3 µM of  forward primer - 5’-GAT ACC ACG TTC CGT 
CTG G-3’ (Hindiyeh et al., 2008), 0.3 µM of reverse primer - 5’-GCA GGT TCC GGT TTT 
GTC TC-3’ (Tenover et al., 2006), and 0.2 µM of  probe -6-carboxyfluorescein-5’-AGC 
GGC AGC AGT TTG TTG ATT G-3’-6 carboxytetramethylrhodamine (Hindiyeh et al., 
2008).  Primers were obtained from Eurofins MWG Operon (Huntsville, AL), and the 
probe was obtained from Life Technologies. 
All PCR assay reactions were performed in duplicate, using a total volume of 25 
µl, containing 5 µl of template DNA (i.e., 10-100 ng) and 20 µl of the master mix 
solution. Positive and negative controls were included with each PCR assay.  Following 
amplification, the results were analyzed on the PCR computer using the SDS ver. 3.0 
software. Once amplification was completed, the level of amplification was reported by 
the software as the mean Cycle Threshold (CT) value of replicate samples.  CT refers to 
the PCR cycle at which fluorescence (i.e., amplification product) is first detected.  A 
sample was considered positive by real-time PCR and possessed the blaKPC gene, if the 
CT crossed the threshold before the threshold cycle of 40. A  CT value of 40 or 
undetermined represents no target DNA present. Samples that tested undetermined for 
the blaKPC gene were re-analyzed using an Internal Positive Control (IPC) (Life 
Technologies) to determine if there were inhibitors present in the reaction. 
 
Internal Positive Control 
  A commercially available TaqMan exogenous Internal Positive Control (Life 
Technologies) was used to detect PCR inhibition and rule out false negatives.  The kit 
included 10X Exogenous IPC Primer and Probe (VIC™ Probe) mix, 10X Exogenous IPC 
Blocking Reagent, and 50X Exogenous IPC DNA.  The blaKPC PCR assay was run with the 
internal positive control; thus, absence or a decrease in amplification of the IPC DNA in 
each duplex PCR indicated the presence of PCR inhibitors. Several dilutions (i.e., 10-1 to 
10-3) of selected DNA samples were tested, to determine and eliminate potential PCR 
inhibitors. 
Antimicrobial Susceptibility Testing (AST) and Microbial Identification 
All clinical isolates were subjected to carbapenem Antibiotic Susceptibility 
Testing (AST) using gram-negative (GN) AST and identification cards for the Vitek 2 
Compact system (bioMerieux, Durham, NC) following the manufacturer’s protocol. AST-
GN69 and AST- XN06 Vitek 2 Gram negative cards were used for AST, and for microbial 
identification, Vitek 2 GN ID card ref. 21341 was used (Appendices A and B).  Briefly, the 
clinical isolates were sub-cultured (from the refrigerator stocks or from the freezer 
when there was no growth) onto TSA and incubated for 18-24 hours at 35°C in ambient 
air. A cell suspension of each sample with optical density of 0.5 – 0.63 McFarland 
Standard was prepared. The suspension was loaded onto the ID and AST cards in the 
biological safety cabinet, and then transferred to the Vitek 2 Compact machine for 
analysis.  The results of the susceptibility profile were analyzed on the Vitek 2 system 
computer using software version 5.04 (bioMerieux) according to the U.S. Food and Drug 
Administration (FDA) (previous CLSI breakpoints) and the Current CLSI carbapenem 
susceptibility breakpoints (Table 1). Furthermore, the Advanced Expert Analysis (AES) 
was applied to our analysis to determine the phenotype of carbapenem resistance 
implicated in our isolates. AES uses the knowledge base of the Vitek 2 system ver. 5.04 
to determine resistance profile, resistance phenotype, and therapeutic interpretation of 
the results. AES uses all information available rather than MIC values alone to determine 
resistance. In some cases, isolates may have susceptible MIC yet be classified as non-
susceptible by AES. 
Statistical Analysis 
Results were analyzed to determine if there was any significant difference 
between carbapenem susceptibility and non-susceptibility among individual antibiotics 
when using the previous and the current CLSI breakpoint criteria. We also determined if 
there was a statistically significant difference between the carbapenem susceptibility 
profiles among blaKPC gene positive isolates when using the previous and the current 
breakpoints. For our data, a non-parametric analysis (i.e., the Fisher Exact Test) was 
used.  All analyses were conducted using SPSS ver. 22.0 (IBM, Armonk, New York). 
 
RESULTS 
Test Organisms 
Fifty-six isolates were received and sub-cultured on TSA, and incubated for 24-48 
hours.  Of these, one did not grow after various attempts to culture it.  Two additional 
isolates had the same  identification number; therefore, one of these was not analyzed.  
In total, 54 out of 56 isolates received were included in our analysis.  These isolates 
were recovered from urine (catheter, and clean catch; n=27), sputum (n=16), bronchiole 
(n=1), wound (n=5), abscess (n=1), blood (n=2), abdominal fluid (n=1), and unspecified 
location (n=3). 
Template DNA Concentration 
The amount of DNA present in 100 µl of each DNA extract was measured after 
DNA extraction. The mean DNA concentration of all of the isolates from duplicate 
measurements varied from 8.8 ng/l to 131.3 ng/l (Table 3). Subsequently, all DNA 
extracts with a concentration greater than 21 ng/l were diluted. The final DNA 
concentration in 5 µl of sample used for the PCR assay ranged from 10.7 ng to 94.0 ng. 
The UV- Visible spectrophotometer determines the DNA concentration by using 
the ratio of DNA absorption at 260 nm to absorption of RNA at 280 nm. The average 
260/280 absorption ratio measured ranged from 0.033 to 8.188 (Table 3). 
Real- Time Polymerase Chain Reaction (PCR) Analysis 
All isolates with mean CT values <40 were regarded as positive, and thus 
considered to harbor the blaKPC gene. Known KPC gene negative ATCC strains (i.e., K. 
pneumoniae ATCC 13883, K. pneumoniae ATCC 4352, K. pneumoniae ATCC BAA 1706, 
and K. pneumoniae ATCC 700603) all tested PCR negative (undetermined) for the 
presence of the blaKPC gene (Table 3). All known KPC gene positive strains obtained 
from ATCC (i.e., Enterobacter hormaechei ATCC BAA 2082 and Klebsiella pneumoniae 
ATCC BAA 1705) tested positive for the KPC gene with mean CT values of 17.1 and 18.8, 
respectively (Table 3).  
Ten out of 54 isolates produced undetermined (i.e., negative) results with PCR 
and were regarded as negative for the blaKPC gene. Additional PCR analyses performed 
with the Internal Positive Control (IPC) on isolates that were negative showed inhibition 
in several blaKPC gene negative isolates. Subsequently, serial dilution (1:10 and 1:100) 
of the inhibited samples resulted in a positive blaKPC gene by PCR (Table 4). The 
prevalence rate of blaKPC gene among 54 suspected CRE isolates received from Quest 
Diagnostics in Las Vegas was 83.3%, and the prevalence of the blaKPC gene among 
Klebsiella pneumoniae isolates (identified with the Vitek 2 Compact instrument) was 
93.6%. 
 
  
Table 4: Internal Positive Control (IPC) PCR Results of blaKPC Gene Negative Isolates 
     NTC = No Template Control  
 
Sample  Dilution 
blaKPC  
(Mean Ct Value; n=2) 
IPC   
(Mean Ct; n=2) 
NTC N/A undetermined 31.85 
Klebsiella pneumoniae  
ATCC BAA 1705 
  
1:10 18.80 undetermined 
1:100 22.53 undetermined 
1:1000 26.85 32.11 
CRE 004 
  
  
Undiluted undetermined undetermined 
1:10 undetermined 32.68 
1:100 undetermined 32.66 
CRE 021 1:10 undetermined 31.31 
CRE 029 
  
  
Undiluted undetermined undetermined 
1:10 undetermined 32.34 
1:100 undetermined 31.74 
CRE 033 
  
Undiluted undetermined 34.07 
1:10 undetermined 32.20 
CRE 036 1:10 undetermined 30.90 
CRE 039 
  
Undiluted undetermined 33.53 
1:10 undetermined 31.99 
CRE 040 1:10 undetermined 31.12 
CRE 042 
  
  
Undiluted undetermined undetermined 
1:10 22.02 undetermined 
1:100 25.79 35.26 
CRE 050 
  
1:10 undetermined 32.07 
1:100 undetermined 31.84 
CRE 052 1:10 undetermined 31.50 
Identification of Isolates 
 Microbial identification carried out on CRE isolates using the Vitek 2 ID card No. 
21341 identified the following organisms with at least 94% confidence (Table 5): 
Klebsiella pneumonia pneumoniae (n=46), Escherichia coli (n=2), Enterobacter aerogenes 
(n=2), Citrobacter freundii (n=2), Acinetobacter baumannii (n=1), and Proteus mirabilis 
(n=1). 
 
Table 5: Organisms Identified by Vitek 2 ID Analysis. 
Organisms Identified N 
Acinetobacter baumannii 1 
Citrobacter  freundii 2 
Klebsiella pneumoniae 46 
Proteus mirabilis 1 
Enterobacter aerogenes 2 
Escherichia coli 2 
 
 
Antibiotic Susceptibility Testing (AST) 
The Vitek 2 instrument was used for AST of ATCC reference samples and CRE 
isolates, and these were analyzed using the current and the previous CLSI MIC 
breakpoints. Our reference samples included three known KPC negative species from 
ATCC (Klebsiella pneumoniae ATCC 13883, Klebsiella pneumoniae ATCC 4352, and 
Klebsiella pneumoniae ATCC 700603), and two known KPC positive species (Enterobacter 
hormaechei ATCC BAA 2082 and Klebsiella pneumoniae ATCC BAA 1705). Carbapenem 
non-susceptibility (i.e., resistance) was concluded for all samples with intermediate or 
resistant MIC results.  Analysis of the ATCC negative reference samples using both 
criteria (previous and current CLSI breakpoints), showed susceptibility to all 
carbapenems. All KPC positive ATCC controls were non-susceptible to all carbapenems 
(Table 6). 
 
Table 6: ATCC blaKPC Positive and Negative Organisms and their AST Results. 
 
  
Test Organism 
CLSI Criteriaa 
2009 2012 2009 2012  2009  2012 2009 2012  
Ertapenem Imipenem  Doripenem Meropenem 
K. pneumoniae  
ATCC 13883 
S S S S S S S S 
K. pneumoniae  
ATCC 4352 
S S S S S S S S 
K. pneumoniae  
ATCC 700603 
S S S S S S S S 
E. hormaechi  
ATCC BAA 2082 
R R I R nd R R R 
K. pneumoniae  
ATCC BAA 1705 
R R R R nd R R R 
 ATCC- American Type Culture Collection; S = Susceptible; I = Intermediate; R= Resistant; nd = no       
criteria available for 2009. 
a 2009 represents previous criteria and 2012 represents current criteria. 
 
Ertapenem Susceptibility Testing 
According to the Vitek 2, Ertapenem use was not indicated for clinical use in one 
of our 54 CRE isolates. This resulted in 53 isolates that were analyzed with the previous 
and current CLSI criteria for this antibiotic. Using current breakpoints (CLSI M100-S22) 
for susceptibility interpretations, 48 of our 53 isolates (90.6%) showed resistance (i.e., 
non-susceptibility) to Ertapenem, and 5 isolates (9.4%) were susceptible for this 
antibiotic (Table 7). However, when using the previous breakpoints (CLSI M100-S19), 47 
isolates (88.7%) were resistant and 6 isolates (11.3%) were susceptible to Ertapenem. 
Transitioning to the current CLSI criteria for this antibiotic would result in a change in 
resistance rate from 88.7% to 90.6%. 
Imipenem Susceptibility Testing 
Using the current Imipenem breakpoints, 49 of 54 isolates (90.7%) were 
classified as resistant, and five isolates (9.3%) were classified as susceptible (Table 7). In 
terms of the previous breakpoints, Imipenem resistance occurred in 46 of 54 isolates 
(85.2%), with 8 isolates (14.8%) classified as susceptible. Transitioning to the current 
CLSI criteria for Imipenem would result in a change in resistance rate from 85.2% to 
90.7%. 
Doripenem Susceptibility Testing 
According to the Vitek 2, Doripenem was not indicated for clinical use in two of 
our  54 CRE isolates. This resulted in 52 isolates that were analyzed with the previous 
and current CLSI criteria for this antibiotic. Doripenem MIC interpretations with the 
current breakpoints classified 47 of 52 isolates (90.4%) as non-susceptible and 5 isolates 
(9.6%) as resistant (Table 7). Doripenem is a fairly new carbapenem antibiotic; 
therefore, there were no susceptibility interpretations published for it in the previous 
CLSI breakpoints. Thus, we cannot make a comparison between the previous and 
current carbapenem breakpoints.   
Meropenem Susceptibility Testing 
For Meropenem, resistance was reported in 49 of 54 isolates (90.7%) when using 
the current CLSI breakpoints, but with the previous breakpoints Meropenem resistance 
was reported in 47 of 54 (87.0%) isolates, with 7 isolates (13.0%) showing susceptible to 
this antibiotic (Table 7).  Transitioning to the current CLSI criteria for Meropenem would 
result in a change in resistance rates from 87.0% to 90.7%. 
 
Table 7: Individual Carbapenem Susceptibility Among all CRE Isolates Analyzed. 
 
Individual 
carbapenems 
Previous Breakpoints 
(M100-S19) 
Current Breakpoints 
(M100-S22) 
Susceptible Non-susceptible Susceptible 
Non-
susceptible 
N % N % N % N % 
Ertapenema 6 11.3 47 88.7 5 9.4 48 90.6 
Imipenem 8 14.8 46 85.2 5 9.3 49 90.7 
Doripenemb nd nd nd nd 5 9.6 47 90.4 
Meropenem 7 13.0 47 87.0 5 9.3 49 90.7 
aErtapenem use was not indicated for 1 isolate.  bDoripenem use was not indicated for 2 
isolates.  nd = Doripenem interpretation was not defined in the Previous Breakpoints. 
 
Ertapenem Susceptibility of blaKPC Gene Negative Isolates 
Of the nine CRE isolates that were negative for the blaKPC gene, the Vitek 2 
analysis indicated that eight of these should have been treated with Ertapenem (Table 
8). When using the previous breakpoints, six of these isolates were susceptible to 
Ertapenem (i.e., two isolates were non-susceptible or resistant). When the MICs were 
analyzed with the current breakpoints, five were classified as susceptible to Ertapenem 
and three as resistant. Therefore, there was only one blaKPC gene negative isolate 
which reported susceptibility to Ertapenem with the previous criteria, but changed to 
resistant with the current criteria (Table 9). 
Imipenem Susceptibility of blaKPC Gene Negative and Positive Isolates 
All nine of the blaKPC gene negative isolates were indicated for treatment with 
Imipenem.  When analyzed with the previous CLSI criteria, seven isolates were classified 
as susceptible to Imipenem, while two isolates were resistant (Table 8). With the current 
breakpoints, five of the nine isolates were susceptible to Imipenem, while four were 
resistant. Transitioning to the current CLSI criteria would result in two blaKPC gene 
negative isolates previously reported as susceptible for Imipenem that now would be 
reported as resistant with the current breakpoints (Table 9). On the other hand, only 
one blaKPC gene positive that was susceptible to Imipenem when using the previous 
breakpoints changed to resistant with the current breakpoints (Table 9). 
 
Table 8: Individual Carbapenem Susceptibility Among blaKPC Gene Negative Isolates. 
Individual 
carbapenems 
  
  
Previous Breakpoints  
(M100-S19) 
Current Breakpoints  
(M100-S22) 
Susceptible 
Non-
Susceptible 
Susceptible 
Non-
Susceptible 
Ertapenem  6 2 5 3 
Imipenem 7 2 5 4 
Doripenem nd nd 4 3 
Meropenem 7 2 5 4 
    nd = Doripenem interpretation was not defined in the previous breakpoints 
 
 
Table 9: Susceptibility Changes (Susceptible to Non-Susceptible) Between the Previous CLSI 
Criteria and the Current Criteria Among blaKPC Genes (Negative and Positive). 
Individual 
carbapenemsa 
blaKPC Gene 
Negative 
blaKPC Gene 
Positive 
Total number 
of changes 
Ertapenem  1 0 1 
Imipenem 2 1 3 
Meropenem 2 0 2 
a Doripenem susceptibilities were not compared. 
Doripenem Susceptibility of blaKPC Gene Negative Isolates 
For blaKPC gene negative isolates that were indicated for treatment with 
Doripenem (n= 7), analysis with the current CLSI breakpoints reported only four isolates 
as susceptible to Doripenem while three were resistant (Table 8). We cannot make a 
comparison between the previous and current breakpoints for this antibiotic because 
there were no susceptibility interpretations published for it in the previous CLSI 
breakpoints (Table 9). 
Meropenem Susceptibility of blaKPC Gene Negative Isolates 
When using the previous breakpoints, Meropenem susceptibility was seen in 
seven of nine blaKPC gene negative isolates, while two isolates were resistant to this 
antibiotic (Table 8). With the current breakpoints, five isolates were susceptible to 
Meropenem, and four were resistant.  Transitioning to the new CLSI criteria would 
result in two blaKPC gene negative isolates previously reported as susceptible to 
Meropenem that now would be reported as resistant with the current breakpoints 
(Table 9). 
Carbapenem Susceptibility of blaKPC Gene Positive Isolates 
Among blaKPC gene positive isolates, individual carbapenem susceptibility 
profiles did not vary much between the previous criteria and the current CLSI criteria 
(Table 10).  All blaKPC gene positive isolates (n=45) reported resistance to Ertapenem 
and Meropenem across the two criteria. Thus, non-susceptibility rate among blaKPC 
gene positive isolates continued to be the same at 100% for Ertapenem and 
Meropenem, when using the previous and current criteria. However, Imipenem showed 
a change in resistance rate from 97% to 100% when comparing the previous to the 
current CLSI criteria (Table 10).  No data comparisons were possible for Doripenem; 
however, the blaKPC gene positive isolates showed a resistance rate of 98% for this 
antibiotic (with the current criteria) (Table 10). 
 
Table 10: Individual Carbapenem Non-Susceptibility in blaKPC Gene Positive Isolates (n= 45). 
Individual 
carbapenems 
  
  
Previous Breakpoints  
(M100-S19) 
Current Breakpoints  
(M100-S22) 
Susceptible Non-Susceptible Susceptible Non-Susceptible 
Ertapenem  0 45 (100%) 0 45 (100%) 
Imipenem 1 44 (97.8%) 0 45 (100%) 
Doripenem nd nd 1 44 (97.8%) 
Meropenem 0 45 (100%) 0 45 (100%) 
    nd = Doripenem interpretation was  not defined in the previous breakpoints 
 
Mechanisms of Antibiotic Resistance 
Many isolates reported different and more than one resistance phenotype when 
the Expert Analysis (AES) from the Vitek 2 instrument was applied to our AST analysis. 
The resistance phenotypes (or mechanism of resistance) reported for all isolates were 
different depending on the AST card used (Table 8). Analysis with the GN 69 AST card 
reported the following resistance phenotypes for our isolates:  Extended Spectrum Beta-
Lactamase (ESBL), Impermeability (carbapenems and cephamycins), carbapenemase 
(Metallo- or KPC), Penicillinase (acquired or wild type), and High Level AmpC (HL-CASE) 
(Table 11).  
Analysis with the GN XN 06 AST card showed the following resistance 
phenotypes:  ESBL, Impermeability (carbapenems and cephamycins), carbapenemase 
(Metallo- or KPC), Inhibitor Resistant PASE (IRT or OXA), Penicillinase, and High Level 
AmpC (Table 11).  Regardless of the AST card used, the three most common resistance 
mechanisms observed were: ESBL (87%), Impermeability (85.2%), and carbapenemase 
(83.3%). 
 
Table 11: Carbapenem Resistance Phenotypes Implicated in all Isolates (n=54). 
 
 a Most isolates exhibited more than one phenotype. 
 
The nine isolates that were negative for the blaKPC gene were identified (Table 
12). According to the Vitek 2 Advanced Expert Setting Analysis (AES), resistance 
phenotypes for these isolates were ESBL, Impermeability, carbapenemase (Metallo- or 
KPC), Penicillinase (acquired or wild type), High Level-Case (amps), and Inhibitor 
Resistant PASE (IRT or OXA) (Table 12).  
 
 
 
 
 
Carbapenem Resistance Phenotypea 
GN 69 AST Card  
(N; percentage) 
GN XN 06 AST 
Card (N; 
percentage) 
Extended Spectrum Beta- lactamase 47 (87.0%) 47 (87.0%) 
Impermeability (carbapenems and cephamycins) 46 (85.2%) 48 (88.8%) 
Carbapenemase (Metallo- or KPC) 45 (83.3%) 49 (90.7%) 
Penicillinase (acquired or wild type)  2 (3.7%) 1 (1.9%) 
High Level AmpC (HL-CASE)  2 (3.7%) 1 (1.9%) 
Inhibitor Resistant PASE (IRT or OXA)  0 (0%) 1(1.9%) 
Table 12: Carbapenem Resistance Phenotype Implicated in all blaKPC Negative Isolates. 
aHL-Case (AmpC) – High Level AmpC  
 
Isolates that Changed from Susceptible to Non-Susceptible Between 2009 and 2012 
Breakpoints 
Five isolates changed from susceptible to non-susceptible in at least one carbapenem 
when using the current criteria.  Four of these where blaKPC gene negative (Table 13). 
Carbapenemase (Metallo- or KPC) were implicated as the mechanism of resistance in 
four of these. Other resistance mechanisms implicated included ESBL, AmpC, and 
Impermeability. Specifically these isolates included three non-Klebsiella species and two 
Klebsiella pneumoniae. 
  
Organisms ID N Resistance Phenotype (GN 69/XN 06 AST Card) 
Acinetobacter baumannii 1 Impermeability 
Citrobacter freundii 1 carbapenemase (Metallo- or KPC) 
Klebsiella pneumoniae 3 
Penicillinase, Inhibitor Resistant PASE (IRT or OXA), ESBL, 
Impermeability 
Proteus mirabilis 1 ESBL/carbapenemase (Metallo- or KPC) 
Enterobacter aerogenes 2 
ESBL/HL-Case (AmpC)a, Impermeability, carbapenemase 
(Metallo- or KPC) 
Escherichia coli 1 Penicillinase/ Inhibitor Resistant PASE (IRT or OXA) 
Table 13: List of Isolates that Changed in AST Between the Previous and the Current Breakpoints  
Isolates Organism ID 
blaKPC 
status 
Carbapenem 
implicated AES Resistance Phenotypes 
CRE 021 
Citrobacter 
freundii Negative 
Imipenem, 
Meropenem Carbapenemase (Metallo- or KPC) 
CRE 033 
Proteus 
mirabilis Negative Meropenem 
ESBL, Carbapenemase (Metallo-or 
KPC) 
CRE 050 
Enterobacter 
aerogenes Negative Imipenem 
AmpC, Impermeability, 
Carbapenemase (Metallo-or KPC) 
CRE 052 
Klebsiella 
pneumoniae Negative Ertapenem ESBL, Impermeability 
CRE 053 
Klebsiella 
pneumoniae Positive Ertapenem 
ESBL, Impermeability, 
Carbapenemase (Metallo- or KPC) 
 
 
Susceptibility to other Antibiotics 
 In our study, susceptibility of CRE to gentamicin, ceftazoxime and cefepime were 
relatively high at 57%, 44% and 41%, respectively.  
Statistical Analysis 
Results were analyzed to determine if there was any significant difference 
between carbapenem susceptibility and non-susceptibility among individual antibiotics 
when using the previous and the current breakpoint criteria. Statistical analysis using 
Fisher’s Exact Test on AST with the previous and current criteria for Ertapenem, 
Imipenem, and Meropenem were not significantly different (p-values > 0.05). Therefore, 
we failed to reject the null hypothesis (H01) of equal proportion in carbapenem 
resistance between the previous and the current CLSI breakpoint criteria.  
Statistical analysis to determine if there was a significant difference between the 
carbapenem susceptibility profiles among isolates with the blaKPC gene when using the 
previous and the current breakpoints were not significantly different (p-values > 0.05). 
We failed to reject the null hypothesis (Ho2) that there is no difference in carbapenem 
susceptibility profiles among KPC gene positive isolates between the current and the 
previous CLSI breakpoints. 
 
DISCUSSION 
 
 In 2012, the Clinical and Laboratory Standards Institute (CLSI) published updated 
editions of its antimicrobial susceptibility testing (AST) standards.  The updated criteria 
are intended to detect emerging bacterial resistance.  Periodic updates of these 
guidelines are necessary because bacteria acquire resistance to antibiotics over time, 
and using the most current knowledge ensures that infections are treated consistently 
and fosters good antibiotic stewardship. In recent times, automated AST systems have 
become the most common method of conducting susceptibility testing; these 
instruments measure the minimal inhibitory concentration of antibiotics using the CLSI 
guidelines. The FDA considers non-susceptibility to antibiotics as MIC results that are 
intermediate or resistant according to fixed breakpoints; in addition, the agency is 
responsible for approving the use of CLSI criteria with automated AST systems.  The 
lower MIC for carbapenem antibiotics established for KPCs in 2012 by the CLSI have not 
been endorsed by the FDA.  Therefore, data were needed to estimate the percentage of 
clinical isolates that are potentially resistant to carbapenems by determining the 
presence of the KPC gene. Detecting the presence of the KPC gene is important because, 
the use of carbapenems determined by using the current breakpoints for infections may 
have poor clinical outcomes if the gene is present. Conversely, if the KPC gene is absent, 
treatment with carbapenems may still be indicated. The objectives of this study were to 
determine carbapenem AST profiles, resistance rates based on the previous and current 
CLSI criteria, and the presence of the KPC gene in CRE isolates. 
In this study, carbapenem resistance among CRE isolates was mainly seen among 
Klebsiella pneumoniae (87%), followed by E. coli, Enterobacter aerogenes, and 
Citrobacter freundii, each with 3.7%. Acinetobacter baumannii and Proteus mirabillis 
(1.9% each) were also identified in our study as being resistant to carbapenems. Our 
results are similar to other published articles on CREs in which Klebsiella spp. are the 
most commonly reported Enterobacteriaceae with non-susceptibility to carbapenems. 
In a study by Jacob et al. (2013), the most commonly reported organism among 72 CRE 
isolates were Klebsiella species (n=49), with Enterobacter species and E. coli contributing 
14 and 10 isolates, respectively (Jacob et al., 2013).  We also observed that urine 
samples (27 out of 54) were the most common site of CRE isolation, followed closely by 
respiratory isolates (17 out of 54). Jacob et al. also identified CREs in urine samples more 
frequently (89%) than in other sites.  
The prevalence rate of the blaKPC gene was 83.3% among suspected CRE isolates 
from different healthcare centers in Nevada, determined in our study. Isolates identified 
as Klebsiella pneumoniae comprised the majority of our CRE isolates, and 93.6% of these 
had the blaKPC gene. These rates and findings are similar to other studies in the U.S. 
that reported the blaKPC gene as the most commonly implicated gene in carbapenem 
resistance among the Enterobacteriaceae (Deshpande, Rhomberg, Sader, & Jones, 
2006). Also, the prevalence of the blaKPC gene among Klebsiella pneumoniae identified 
in our study was similar to that reported in other studies published in the U.S., and 
abroad (Nordmann, Cuzon, & Naas, 2009). A study (Shanmugam, Meenakshisundaram, 
& Jayaraman, 2013) in India reported a blaKPC gene prevalence rate of 67.4% among 
CREs, and other recent studies have reported a blaKPC gene prevalence between 82% 
and 100% (Mosca et al., 2013; Raghunathan, Samuel, & Tibbetts, 2011; Shanmugam et 
al., 2013). Although CREs have been recently reported in Nevada, to our knowledge, this 
is the first published report of prevalence of KPC-producing Enterobacteriaceae isolated 
from patients in southern Nevada.  
 The CLSI and the Centers for Disease Control and Prevention recommend that 
CRE isolates with antibiotic resistant profiles or elevated, but susceptible profiles, be 
confirmed with the Modified Hodge Test (Clinical and Laboratory Standards Institute, 
2009). While the Modified Hodge Test has deficiencies, it has remained the first step in 
detecting carbapenemase activity in clinical isolates in many facilities for isolates with 
elevated MIC, and thus, it is particularly important as part of an early infection control 
program. In this study, we used a PCR-based assay as an alternative to verify 
carbapenem resistance among CRE isolates.  
 The recently published CLSI standards for carbapenems have been met with 
mixed reception. Some researchers have argued that the change may only increase the 
false positive results in AST analysis, and thus lead to unnecessary and expensive 
treatments (Po-Yu Liu et al., 2014).  In our study, we found no difference between 
carbapenem resistance in clinical isolates with the previous and the current breakpoints. 
Also, there was no difference between susceptibility profiles among blaKPC gene 
positive isolates when using the two criteria. Therefore, we conclude that the current 
CLSI criteria may not offer additional benefit in the fight against CREs. Our results are 
similar to others reported in the literature that showed either no change between the 
two breakpoints or unnecessary increase in the estimation of carbapenem resistance 
(Hombach, Bloemberg, & Bottger, 2012; Metwally, Gomaa, Attallah, & Kamel, 2013).  
 We used the Expert Analysis (AES) available with our automated AST instrument 
to determine the resistance phenotype of isolates that tested negative for the blaKPC 
gene, yet tested non-susceptible (resistant) to carbapenems during our AST analysis. 
The AES reported Impermeability, carbapenemase (metallo- or KPC), ESBL, and HL-Case 
(AmpC), as the commonly involved mechanisms of resistance among blaKPC gene 
negative isolates using both the previous and current criteria. Impermeability is the 
inability of an antibiotic to penetrate the cell wall of the organism.  Carbapenemases 
and Extended Spectrum β-lactamases (ESBL) work by hydrolyzing the β-lactam structure 
of the antibiotic (David L Paterson & Bonomo, 2005). While ESBL do not hydrolyze 
carbapenems and cephamycins, carbapenemases hydrolyze all groups of -lactams. 
High Level Case (HL-Case) AmpC’s mechanism of resistance involves hydrolysis of β-
lactams, especially cephalosporin through a plasmid mediated cephalosporinase 
(George A Jacoby, 2009). Because our PCR assay was designed to detect only the blaKPC 
gene, it is possible that Metallo-beta-lactamase (MBL) may still be involved in isolates 
with carbapenemase (metallo- or KPC) phenotypes. The MBL is a less common 
carbapenem resistance mechanism, but has been increasing in prevalence in recent 
reports (Centers for Disease Control and Prevention, 2010; Rolain, Parola, & Cornaglia, 
2010; Tijet et al., 2011).  
 Other carbapenem resistance phenotypes that we observed were 
Impermeability and HL-Case (AmpC), and these were mainly seen in non-Klebsiella 
pneumoniae organisms. These findings are in agreement with several published reports 
showing that Impermeability and AmpC enzymes are carbapenem resistance 
phenotypes commonly implicated in other Enterobacteriaceae such as Citrobacter spp., 
Enterobacter spp., and Proteus mirabilis (Mainardi et al., 1997; Mammeri, Nordmann, 
Berkani, & Eb, 2008). Our study also supports that ESBL is commonly involved in 
resistance mechanisms of CREs along with carbapenemase (Thomson, 2010). 
 Because the amount of antibiotics used on patients and the development of 
resistance are directly proportional, increased reports of Enterobacteriaceae resistant to 
carbapenems and reduced MIC breakpoints (current CLSI criteria) will increase the 
number of Enterobacteriaceae determined to be resistant to at least one agent in any 
antimicrobial category. Therefore, it is anticipated that clinicians and healthcare workers 
will most likely prescribe increased doses of carbapenems or other antimicrobial classes 
which may lead to more resistance (Magiorakos et al., 2012). 
Infections caused by CREs are difficult to treat, but with early detection in 
combination with prompt implementation of infection prevention and control practices, 
the high morbidity and mortality rate associated with CREs may be reduced (Cohen et 
al., 2011; Kochar et al., 2009). The CDC categorically recommend through their CRE 
toolkit, an aggressive implementation of infection prevention and control strategies 
once CREs are detected  (Centers for Disease Control and Prevention, 2012b). 
Prevention interventions, such as patient isolation, active surveillance cultures, patient 
cohorting, and education, have been effective in decreasing the incidence of CREs 
(Ciobotaro, Oved, Nadir, Bardenstein, & Zimhony, 2011; Debby Ben‐David et al., 2010). 
In terms of chemotherapy, the limited treatment alternatives that exist for 
patients with CRE infections include the use of combination therapies involving 
carbapenems, tigeycline, colistin, amikacin, and polymixin (Castanheira et al., 2009; 
Neuner et al., 2011).  We determined that gentamicin, ceftizoxime and cefepime had 
relatively high susceptibilities among CREs in our study. Whether or not these agents 
demonstrate clinical success, especially in severe CRE infections, remains to be 
determined in vivo (Nayman-Alpat et al., 2010). In-vitro combinations of these antibiotics 
have shown bactericidal and synergistic effects (Bratu et al., 2005; Le, McKee, Srisupha-
Olarn, & Burgess, 2011; Pankey & Ashcraft, 2011; Pournaras et al., 2011). However, 
higher toxicity, side effects, limited efficacy, and concerns of spread of resistance have 
limited their use in patients. Resistance to polymyxins and tigeycline or any known 
alternative have also been reported in some case-series studies, and suggest a fresh 
concern of pan-antibiotic resistance among CREs (Elemam, Rahimian, & Mandell, 2009). 
Our study had several strengths and some limitations. The number of isolates 
included in the study was limited; however, our pilot study did provide data that can be 
utilized in further studies. Molecular detection of the blaKPC gene only detected isolates 
that express the KPC gene and may have underestimated the presence of other 
resistance mechanisms implicated in CREs, such as the MBL, the OXA, and the AmpC 
enzymes in blaKPC gene negative isolates. Because Klebsiella pneumoniae 
carbapenemase is the most implicated carbapenemase in the U.S., in a resource limited 
setting, targeting the KPC gene will be a more efficient way to detect and confirm 
carbapenem resistance. We did not perform the MHT as confirmation for 
carbapenemase activity in our CRE isolates as recommended by the CDC; however, we 
were able to use a PCR-based assay as an alternative to verify the Klebsiella pneumonia 
carbapenemase gene. 
 
CONCLUSIONS 
 
Based on our findings, an understanding of the enzymatic mechanisms and other 
phenotypes of resistance mediated by CREs is important in the prevention of these 
organisms. Infections due to isolates that showed impermeability and concomitant 
production of ESBLs may be managed with carbapenems if their MICs are in the 
susceptible range. Although the implementation of the current CLSI breakpoints for 
carbapenem AST can make results more comparable worldwide, especially if it 
corresponds with the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) system. However, evidence-based studies should validate these revised 
guideline changes before their general implementation.  It is also important that 
clinicians and laboratories are aware of the implications of the revised antibiotic 
susceptibility testing reports in clinical practice, such as the effects on antibiotic 
prescription and antibiotic stewardship. In addition, to ensure proper detection of 
emerging resistance, species-related zones of inhibition or MIC breakpoints should be 
published as a means to targeted control of CREs. 
The results of this study are expected to provide health care providers and 
infectious disease specialists an informed interpretation of susceptibilities and antibiotic 
recommendations. It also serves as an important step towards developing targeted 
strategies to control the spread of CREs in our communities. These results will help to 
improve antibiotic stewardship in Nevada by determining the prevalence of the KPC 
gene among CRE isolates from different health institutions in Las Vegas.  
In conclusion, timely intervention, such as good infection control practices, rapid 
detection, and prudent use of antibiotics will ensure that the spread of carbapenem 
resistance among organisms is kept under control.  Future studies should include a real-
time PCR assay that is capable of detecting multiple resistance genes to provide rapid 
and accurate detection of carbapenem resistance.  
APPENDICES 
  
Appendix A – Vitek 2 GN69 Card Information 
 
 
 
 
 
 
 
 
 
 
 
Antibiotics tested 
ESBL Confirmation Test 
Ampicillin 
Amoxicillin/ 
Clavulanic Acid 
Ampicillin/Sulbactam 
Piperacillin/Tazobactam 
Cefazolin 
Ceftazidime 
Ceftriaxone 
Cefepime 
Ertapenem 
Imipenem (new formula) 
Gentamicin 
Tobramycin 
Ciprofloxacin 
Levofloxacin 
Nitrofurantoin 
Trimethoprim/Sulfamethoxazole 
Appendix B – Vitek 2 GN XN06 Card Information 
 
 
 
 
 
  
Antibiotics tested 
Ticarcillin/Clavulanic Acid 
Piperacillin 
Cefalotin 
Cefuroxime 
Cefuroxime Axetil 
Cefotetan 
Cefoxitin 
Cefpodoxime 
Cefotaxime 
Ceftizoxime 
Aztreonam 
Doripenem 
Meropenem 
Amikacin 
Nalidixic Acid 
Moxiflaxacin 
Norfloxacin 
Tetracycline 
Tigecycline 
Table 3: DNA Concentrations and PCR Results for CRE Isolates. 
Test Organism/Sample 
Identification  
 
Average   
260/280 
Ratio 
(n=2) 
Average 
DNA Conc. 
(ng/µl; n=2) 
DNA 
Conc. per 
PCR rxn. 
PCR Results  
 
Mean CT 
Value (n=2) 
SD 
Klebsiella pneumoniae 
ATCC 13883 
1.929    33.8 16.9 undetermined N/A 
K. pneumoniae  
ATCC 4352 
1.767 103.8 51.9 undetermined N/A 
K. pneumoniae  
ATCC BAA 1706 
1.779    37.5 18.8 undetermined N/A 
K. pneumoniae  
ATCC 700603 
1.819    61.3 30.6 undetermined N/A 
Enterobacter hormaechei 
ATCC BAA 2082 
1.811 131.3 65.6 17.14 0.89 
K. pneumoniae  
ATCC BAA 1705 
1.750 38.8 19.4 18.80 0.08 
CRE 001 2.434 28.8 14.4 21.19 0.08 
CRE 002 2.000 25.0 12.5 17.52 0.05 
CRE 003 1.500 21.3 10.6 18.41 0.01 
CRE 004 2.750 8.8 43.8 undetermined N/A 
CRE 005 1.734 25.0 12.5 20.48 0.08 
CRE 006 2.042 17.5 87.5 18.99 0.08 
CRE 007 2.665 16.3 81.3 20.22 0.25 
CRE 008 1.500 13.8 68.8 28.00 2.30 
CRE 009 4.500 18.8 93.8 26.41 2.13 
CRE 010 5.000 12.5 62.5 27.23 0.34 
CRE 011 1.500 8.8 43.8 23.48 0.09 
CRE 012 1.625 16.3 81.3 26.37 1.41 
CRE 013 2.355 30.0 15.0 19.97 0.07 
CRE 014 1.500 11.3 56.5 20.97 0.61 
CRE 015 0.625 21.3 10.7 20.71 0.14 
CRE 016 0.834 18.8 94.0 31.70 0.53 
CRE 017a 2.095 25.0 12.5 20.69 0.17 
CRE 018 1.200 17.5 87.5 23.90 1.24 
CRE 019a 2.200 12.5 62.5 25.15 1.30 
CRE 020 2.084 23.8 11.9 19.61 0.15 
CRE 021 8.188 25.0 12.5 undetermined N/A 
CRE 022 5.000 17.5 87.5 25.10 0.38 
CRE 023 1.684 22.5 11.3 20.79 0.20 
CRE 024 3.179 27.5 13.8 20.28 0.00 
CRE 025 1.000 15.0 75.0 24.02 0.21 
CRE 026 1.800 11.3 56.5 23.42 0.11 
Test Organism/Sample 
Identification  
 
Average   
260/280 
Ratio 
(n=2) 
Average 
DNA Conc. 
(ng/µl; n=2) 
DNA 
Conc. per 
PCR rxn. 
PCR Results  
 
Mean CT 
Value (n=2) 
SD 
CRE 027 1.072 17.5 87.5 19.79 0.85 
CRE 028 0.417 3.8 19.0 24.91 0.08 
CRE 029 0.834 15.0 75.0 undetermined N/A 
CRE 030 1.000 20.0 100.0 25.94 0.08 
CRE 031 1.272 18.8 94.0 18.12 0.13 
CRE 032 1.083 16.3 81.5 21.81 0.17 
CRE 033 0.650 7.5 37.5 undetermined N/A 
CRE 034 1.104 21.3 10.7 19.04 0.16 
CRE 035 1.134 21.3 10.7 19.72 0.03 
CRE 036 1.205 21.3 10.7 undetermined N/A 
CRE 037 1.250 25.0 12.5 19.12 0.06 
CRE 038 1.526 36.3 18.2 17.49 0.07 
CRE 039 1.188 20.0 100.0 undetermined N/A 
CRE 040 2.028 47.5 23.8 undetermined N/A 
CRE 041 1.258 31.3 15.7 19.26 0.07 
CRE 042 1.143 17.5 87.5 undetermined N/A 
CRE 043 1.320 35.0 17.5 18.35 0.05 
CRE 044 1.370 32.5 16.3 21.13 0.30 
CRE 045 0.033 2.5 12.5 23.91 0.37 
CRE 046 1.252 37.5 18.8 18.23 0.03 
CRE 047 1.438 23.8 11.9 18.80 0.04 
CRE 048 1.243 37.5 18.8 18.70 0.00 
CRE 050 1.091 33.8 16.9 undetermined N/A 
CRE 051 1.774 28.8 14.3 19.59 0.02 
CRE 052 2.000 30.0 15.0 undetermined N/A 
CRE 053 1.835 42.5 21.3 18.18 0.03 
CRE 054 1.956 36.5 18.3 17.92 0.06 
CRE 055 1.772 40.0 20.0 18.81 0.01 
CRE 056 1.571 27.5 13.8 18.74 0.21 
Conc. = concentration; ATCC = American Type Culture Collection; rxn. = reaction; SD = standard 
deviation.  aCRE 017 and CRE 019 are from the same patient. 
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